GENTIAN DIAGNOST. NO -01
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and… Read more
Market Cap & Net Worth: GENTIAN DIAGNOST. NO -01 (6FK)
GENTIAN DIAGNOST. NO -01 (F:6FK) has a market capitalization of $56.99 Million (€55.52 Million) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #21913 globally and #2382 in its home market, demonstrating a 5.26% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GENTIAN DIAGNOST. NO -01's stock price €3.60 by its total outstanding shares 15422350 (15.42 Million).
GENTIAN DIAGNOST. NO -01 Market Cap History: 2021 to 2026
GENTIAN DIAGNOST. NO -01's market capitalization history from 2021 to 2026. Data shows change from $111.76 Million to $56.99 Million (-5.31% CAGR).
GENTIAN DIAGNOST. NO -01 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GENTIAN DIAGNOST. NO -01's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 6FK by Market Capitalization
Companies near GENTIAN DIAGNOST. NO -01 in the global market cap rankings as of March 18, 2026.
Key companies related to GENTIAN DIAGNOST. NO -01 by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
GENTIAN DIAGNOST. NO -01 Historical Marketcap From 2021 to 2026
Between 2021 and today, GENTIAN DIAGNOST. NO -01's market cap moved from $111.76 Million to $ 56.99 Million, with a yearly change of -5.31%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €56.99 Million | -21.91% |
| 2025 | €72.98 Million | +44.06% |
| 2024 | €50.66 Million | -11.60% |
| 2023 | €57.31 Million | -6.46% |
| 2022 | €61.26 Million | -45.18% |
| 2021 | €111.76 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of GENTIAN DIAGNOST. NO -01 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $56.99 Million USD |
| MoneyControl | $56.99 Million USD |
| MarketWatch | $56.99 Million USD |
| marketcap.company | $56.99 Million USD |
| Reuters | $56.99 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.